FGFR4 inhibitor ICP-105

{
  "id": "MLC-T-ONC-013591",
  "term": "FGFR4 inhibitor ICP-105",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.",
  "synonyms": [
    "FGFR4 antagonist ICP-105"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/fgfr4-inhibitor-icp-105/"
}